| Year |
Citation |
Score |
| 2000 |
Hesterlee S, Morton DB. Identification of the cellular target for eclosion hormone in the abdominal transverse nerves of the tobacco hornworm, Manduca sexta. The Journal of Comparative Neurology. 424: 339-55. PMID 10906707 DOI: 10.1002/1096-9861(20000821)424:2<339::Aid-Cne11>3.0.Co;2-Z |
0.309 |
|
| 1996 |
Hesterlee S, Morton DB. Insect physiology: the emerging story of ecdysis. Current Biology : Cb. 6: 648-50. PMID 8793284 DOI: 10.1016/S0960-9822(09)00439-4 |
0.309 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2007 |
Mendell JR, Csimma C, McDonald CM, Escolar DM, Janis S, Porter JD, Hesterlee SE, Howell RR. Challenges in drug development for muscle disease: a stakeholders' meeting. Muscle & Nerve. 35: 8-16. PMID 17068768 DOI: 10.1002/mus.20686 |
0.109 |
|
| 2017 |
Hesterlee S, Amur S, Bain LJ, Carulli J, Clarke S, Day JW, Gagnon C, Hagerman K, Heatwole C, Johnson NE, Moxley R, Patel N, Thornton C, Kessel W, White M. Patient-Centered Therapy Development for Myotonic Dystrophy: Report of the Myotonic Dystrophy Foundation-Sponsored Workshop. Therapeutic Innovation & Regulatory Science. 51: 516-522. PMID 30227044 DOI: 10.1177/2168479016683988 |
0.088 |
|
| 2015 |
Heslop E, Csimma C, Straub V, McCall J, Nagaraju K, Wagner KR, Caizergues D, Korinthenberg R, Flanigan KM, Kaufmann P, McNeil E, Mendell J, Hesterlee S, Wells DJ, Bushby K, et al. The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development. Orphanet Journal of Rare Diseases. 10: 49. PMID 25902795 DOI: 10.1186/s13023-015-0258-1 |
0.081 |
|
| 2023 |
Lek A, Atas E, Hesterlee SE, Byrne BJ, Bönnemann CG. Meeting Report: 2022 Muscular Dystrophy Association Summit on 'Safety and Challenges in Gene Transfer Therapy'. Journal of Neuromuscular Diseases. PMID 36806515 DOI: 10.3233/JND-221639 |
0.081 |
|
| 2019 |
Landrum Peay H, Fischer R, Tzeng JP, Hesterlee SE, Morris C, Strong Martin A, Rensch C, Smith E, Ricotti V, Beaverson K, Wand H, Mansfield C. Gene therapy as a potential therapeutic option for Duchenne muscular dystrophy: A qualitative preference study of patients and parents. Plos One. 14: e0213649. PMID 31042754 DOI: 10.1371/journal.pone.0213649 |
0.079 |
|
| 2018 |
Peay H, Fischer R, Beaverson K, Morris C, Hesterlee S, Ricotti V, Martin A, Rensch C, Wand H, Mansfield C, Smith E. Parent and Adult Patient Attitudes About Gene Therapy as a Therapeutic Option for Duchenne Muscular Dystrophy Value in Health. 21: S256. DOI: 10.1016/J.JVAL.2018.04.1781 |
0.074 |
|
| 2023 |
Kilroy EA, Burris R, Javelosa E, Waits J, Lek A, Rodgers R, Opgenorth H, Hesterlee S. The Muscular Dystrophy Association's neuroMuscular ObserVational Research Data Hub (MOVR): Design, Methods, and Initial Observations. Journal of Neuromuscular Diseases. PMID 36911943 DOI: 10.3233/JND-221551 |
0.067 |
|
| 2007 |
Dunckley T, Huentelman MJ, Craig DW, Pearson JV, Szelinger S, Joshipura K, Halperin RF, Stamper C, Jensen KR, Letizia D, Hesterlee SE, Pestronk A, Levine T, Bertorini T, Graves MC, et al. Whole-genome analysis of sporadic amyotrophic lateral sclerosis. The New England Journal of Medicine. 357: 775-88. PMID 17671248 DOI: 10.1056/Nejmoa070174 |
0.05 |
|
| 2012 |
Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, ... ... Hesterlee SE, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 490: 187-91. PMID 23060188 DOI: 10.1038/Nature11556 |
0.04 |
|
| 2018 |
Levitan B, Getz K, Eisenstein EL, Goldberg M, Harker M, Hesterlee S, Patrick-Lake B, Roberts JN, DiMasi J. Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI's Patient Groups and Clinical Trials Project. Therapeutic Innovation & Regulatory Science. 52: 220-229. PMID 29714515 DOI: 10.1177/2168479017716715 |
0.04 |
|
| 2015 |
Smith SK, Selig W, Harker M, Roberts JN, Hesterlee S, Leventhal D, Klein R, Patrick-Lake B, Abernethy AP. Patient Engagement Practices in Clinical Research among Patient Groups, Industry, and Academia in the United States: A Survey. Plos One. 10: e0140232. PMID 26465328 DOI: 10.1371/Journal.Pone.0140232 |
0.027 |
|
| 2018 |
Bloom D, Beetsch J, Harker M, Hesterlee S, Moreira P, Patrick-Lake B, Selig W, Sherman J, Smith SK, Valentine JE, Roberts JN. The Rules of Engagement: CTTI Recommendations for Successful Collaborations Between Sponsors and Patient Groups Around Clinical Trials. Therapeutic Innovation & Regulatory Science. 52: 206-213. PMID 29714514 DOI: 10.1177/2168479017720247 |
0.019 |
|
| 2001 |
Hesterlee SE. Recognizing risks and potential promise of germline engineering. Nature. 414: 15. PMID 11689914 DOI: 10.1038/35102259 |
0.014 |
|
| Hide low-probability matches. |